on Posterior Segment Emergencies
T. HO, MD, & MATHEW W. MACCUMBER, MD, PHD
Ophthalmologists, particularly retinal specialists,
are faced with a variety of vision-threatening emergencies that must be handled
in an expeditious but careful
manner in order to optimize visual outcome. In
1998, the field was covered in a text edited by one of us entitled Management
of Ocular Injuries and Emergencies (MacCumber MW, ed. Philadelphia, Pa: Lippincott,
Williams & Wilkins, 1998). This update highlights several areas where ocular
emergency management has since changed, focusing on the recent increase in blunt
trauma due to paintball war games and airbags, imaging, management of open-globe
injuries, medical management of choroidal neovascularization (CNV) and retinal vascular
occlusion, and endophthalmitis.
Figure 1. High frequency ultrasound image of
a normal eye (top) and of the opposite eye that developed angle recession after
blunt trauma (bottom).
AND PENETRATING TRAUMA
Worldwide, approximately 55 million eye injuries are believed
to occur yearly, leaving 1.6 million eyes blind.1
Globally, there are approximately 200000 open-globe injuries each year with an estimate
of 3.5/100000/year of perforating eye injuries.1
looked at 1026 open-globe injuries occurring between 1981 and 1999 and found that
the incidence of injuries sustained at work and in traffic accidents decreased over
time, with an associated decreased incidence of blindness and enucleations. Unfortunately,
the incidence of injuries related to hobbies increased during the same period. One
such recreation-related ocular injury that has become prevalent in recent years
is seen with paintball war games.
Conn et al3
analyzed the paintball-related injury data from 1997 to 2001 from the National Electronic
Injury Surveillance System, a data bank of injuries that are reported from a probability
sampling of 100 US hospital emergency departments, and they found an average annual
rate of 4.5 injuries per 10000 participants, with the number treated in hospital
emergency departments more than 3 times higher in 2001 than in 1997. The eye
was found to be the most commonly affected body part (42.7%). At least 85% of those
suffering from eye injuries were either not wearing eye protection or had eye protection
that was temporarily removed due to fogging or paint splattering.
Paintball guns were originally developed for use by foresters
to mark trees for harvest. In the early 1980s, they were adapted for war games and
have increased in popularity over the past 2 decades. Paintball pellets have a face-diameter
of 17 mm (approximately the diameter of a dime) and are 3.5-g gelatin capsules filled
with nontoxic, water-soluble paint designed to rupture on contact. A paint ball
travels at a velocity of 300 feet per second when discharged from CO2-powered
guns and can cause devastating blunt ocular damage through coup and contrecoup effects
and anterior-posterior compression with equatorial expansion. The high velocity,
small size, and high mass of paintballs can result in severe trauma. Anterior segment
complications include lens trauma, angle recession, iridodiaylsis, and, most commonly,
hyphema. Posterior segment complications include choroidal rupture, retinal dialysis
and detachments, open globe injury, and, most commonly, commotio retinae and vitreous
found that 43% of patients had resulting vision of 20/200 or worse.
The American Society for Testing and Materials (ASTM) issued the
Standard Practice for Paintball Field Operations, specifying minimum safety requirements,
which are used voluntarily by most commercial facilities. The ASTM also issued standard
specifications for eye protection devices intended to minimize the risk of eye injuries.
These standards have significantly decreased the rate of paintball-related injuries
in commercial facilities. However, injuries occurring after 1995 were almost 6
times more likely to occur during noncommercial games than those sustained before
1995. This is due to increased availability of paintball equipment, underutilization
of eye protection, and no supervision in "backyard" games. Fineman4
recommended restriction on sales of paintball equipment, public education, and increased
Overall, the most common sources of eye injuries during motor
vehicle accidents (MVAs) are windshields, frontal airbags, steering wheels, and
flying glass. Frontal airbags were mandated starting in 1993 and the combined use
of seat belts and frontal airbags decreased the rate of MVA-related mortality by
45% and severe injury by 50%.6
Before 1993, windshields were the main source of eye injuries, but this was surpassed
by frontal airbags with their availability.7
The major mechanisms of frontal airbag-related eye injuries include contusion with
transfer of energy from the vehicle to the passenger, lacerations, and chemical
burns from sodium hydroxide release. McGwin et al7
looked at the 1988 to 2001 National Automotive Sampling System Crashworthiness Data
System, finding an eye injury rate of 18 in 1000 occupants, with eyelid injuries
and corneal abrasions accounting for 94% of such injuries. Frontal airbag deployment
was associated with a twofold increased risk of eye injuries compared to the twofold
decrease risk associated with seat belt use. Using the same database, Duma et al8
compared the MVA-related eye injury rate with full-powered airbag deployment (1993-1997)
vs depowered airbag deployment (1998-2001) and found a 3.7% and 1.7% rate of eye
injuries, respectively. Pearlman et al6
reviewed the literature published between 1991 and 2000 on 101 patients who sustained
MVA-related eye injuries. They reported that 12.5% of injuries were bilateral and
4.2% were unilateral open-globe injuries. Vitreous or retinal hemorrhage was seen
in 9.9% and retinal tears or detachment was seen in 5.7% of cases. The median visual
outcome was 20/40.6 Lehto
et al9 reviewed the literature
published between 1991 and 2001 on 121 patients and estimated the risk of eye injury
to be 2.5% and serious eye injury to be 0.4%. They also found a threefold increased
risk of open-globe injuries in eyeglass wearers.
Eyes with possible open-globe injuries, especially when intraocular
foreign bodies (IOFBs) are suspected, usually require imaging to confirm the diagnosis
and determine the presence, location, and number of IOFBs. Noncontrast computerized
tomography (CT) scanning has replaced conventional radiography as the diagnostic
study of choice for all forms of ocular trauma. CT provides much more reliable information
on size, shape, and localization of the foreign body, whether in the anterior or
the posterior segment.10-13
Drawbacks of conventional CT include separate scanning in axial and coronal planes
leading to prolonged scanning time and radiation exposure. Reconstruction is limited
by stair-step artifact, compromising detection and localization of small and multiple
foreign bodies, especially those adjacent to the sclera or optic nerve. Volume averaging
also hinders detection and localization of small and multiple foreign bodies.14
Current spiral CT scanning with both 1-mm and
3-mm cuts can detect metallic
IOFB to as small as 0.5 mm with nearly 100% sensitivity.15
Spiral CT allows continuous scanning in less time with volumetric, overlapping data
acquisition, providing multiplanar reconstruction of high-quality coronal and sagittal
images. Thinner slices mean less volume averaging and better detection and localization
of small and multiple foreign bodies. Size and location of IOFBs detected on helical
CT corresponded with what was found during surgical and clinical follow-up.14
In eyes with small, stable wounds, judicious use of B-scan ultrasonography
over closed eyelids has proved useful in detecting retinal detachment (RD), double
perforation, and foreign bodies not otherwise seen on CT, such as vegetative IOFBs.16-18
Using high-frequency (50 MHz) sound waves, ultrasound
biomicroscopy is able to create high-resolution, 2-D cross-sectional anterior
segment images to a depth of 5 mm (Figure 1). It is a useful adjunct in the
detection of small foreign bodies, including those of nonmetallic composition, not
otherwise detected by CT and/or B-scan.19,20
Magnetic resonance imaging is only occasionally useful in the setting of ocular
trauma, such as the detection of radioopaque IOFBs in large, unstable wounds, but
its use must be avoided when iron-containing (ie, metallic) IOFBs are suspected.21-27
coherence tomography (OCT) has revolutionized our ability to detect and differentiate
blunt injuries involving the macula. For example, inner lamellar holes can be difficult
to differentiate from full-thickness macular holes on slit lamp biomicroscopy but
can now be readily diagnosed by OCT, thus improving our ability to advise patients
on prognosis and management (Figure 2).
Management of Open Globe Injuries
All patients with severe ocular injuries should have initial evaluation
to determine primarily whether the globe is open to an extent that requires surgical
intervention in the operating room, whether the patient is medically stable for
surgery, and whether there is an IOFB to plan the surgical approach (ie, primary
vitrectomy for posterior segment IOFB removal).28
The surgeon should take note of certain characteristics of the ocular injury that
are of particular prognostic significance: the mechanism of injury, the presenting
visual acuity, the presence or absence of relative afferent papillary defect, and
the posterior extent of the wound (zone).29
Patients without recent immunization should receive tetanus prophylaxis. In general,
patients should be given systemic antibiotics such as a fourth-generation fluoroquinolone
and, if necessary, antiemetics. In cases of vegetable matter, coverage against Bacillus
species with systemic clindamycin or vancomycin should also be considered. All protruding
foreign material should be left undisturbed and a shield should be placed over every
eye with a suspected open-globe injury until the time of surgical repair (Figure
3). Preoperative topical medication can be withheld if there is risk of disrupting
the wound, especially in the hands of individuals unfamiliar with the management
of eye trauma.
Figure 3. Protruding intraocular foreign body should be shielded
(eg, with a plastic cup) and removed in a controlled fashion in the operating
Traditionally, general anesthesia is utilized in the management
of ocular trauma. However, this is contraindicated in high-risk patients and is
associated with a longer recovery period. Recently, some surgeons have investigated
the use of intravenous sedation with local, or even topical, anesthesia in selected
patients. Scott et al30,31
analyzed 220 eyes with open-globe injuries managed at Bascom Palmer Eye Institute
in Miami between 1995 and 1999 and 238 cases managed between 2000 and 2003. Sixty-four
percent and 59% of these cases, respectively, were performed under intravenous sedation
and regional anesthesia, in the form of retrobulbar or peribulbar blocks with augmentation
after conjunctival cutdown. Patients managed under local anesthesia and intravenous
sedation were more likely to have better presenting visual acuity, IOFBs, and more
anteriorly located and shorter wounds. In addition to the well-known complications
of retrobulbar blocks, care must be taken to prevent expulsion of intraocular content
in the presence of larger wounds. Additionally, Boscia et al32
looked at the use of topical anesthesia and intravenous sedation in 10 open-globe
cases and found it to be a reasonable alternative in less severe injuries.
controversy still exists in surgical management of severe posterior segment injuries.28
The use of prophylactic intravitreal antibiotics varies, but many retinal surgeons
have become more comfortable using such antibiotics in the setting of primary repair
and IOFB. Secondary vitrectomy procedures traditionally occurred at 10 to 14 days
after injury to allow for reduced choroidal congestion and posterior hyaloid separation;
however, technicological improvements can permit vitrectomy sooner and more safely
to prevent fibrous ingrowth and proliferative vitreoretinopathy.33
Personally we prefer vitrectomy within 1 week for severe posterior segment trauma
unless hemorrhagic choroidal detachment demands further delay. There are advocates
for and against prophylactic scleral buckling, but we usually choose to place a
prophylactic encircling scleral buckle for more severe injuries, particularly those
with retinal detachment and when the crystalline lens is preserved.34
Figure 4. Montage
of a perfused central retinal vein occlusion.
Although usually not true ophthalmic "emergencies," sudden vision
loss due to CNV or retinal vascular occlusion (below) often present in an emergent
manner. Progress in the treatment of CNV over the past 10 years has been remarkable.
In 1998, the only proven therapy was photocoagulation, which stabilized or improved
vision primarily only in selected juxtafoveal and extrafoveal cases. Subsequently,
photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) became available
as the first treatment for subfoveal CNV to stabilize and occasionally improve vision.35
Interest in intravitreal triamcinolone acetonide (IVTA, Kenalog, Bristol-Myers Squibb)
added to our ability to treat both CNV and macular edema due to a variety of causes.36
Recently, intraocular antivascular endothelial growth factor (VEGF) inhibition has
become a reality, initially with pegaptanib (Macugen, OSI),37
then bevacizumab (Avastin, Genentech),38
and now ranibizumab (Lucentis, Genentech).39
The remarkable benefit of ranibizumab has been clear in randomized clinical trials
for age-related macular degeneration (AMD).38
We are still learning how to use these therapies alone or in combination for the
management of CNV due to different etiologies, including retinovascular emergencies.
Choroidal ruptures are seen in up to 5% to 10% of blunt ocular
injuries.40 Unlike the sclera
and retina, the retinal pigment epithelium-Bruch's membrane-choriocapillaris complex
is relatively inelastic and may break in a concentric pattern around the optic nerve.
CNV can arise at the site of choroidal ruptures from 1 month to 4 years after injury.41
Both laser photocoagulation and subretinal surgery have been attempted with limited
success. Recently, there have been a few reported cases of choroidal rupture-related
CNV responsive to PDT.42-44
Harrisi-Dagher et al43 looked
at 5 cases that required an average of 2 treatments and found the absence of or
decreased leakage on fluorescein angiogram, with stabilization or improvement in
visual acuity in 80% of cases.
Bevacizumab is a humanized monoclonal antibody that inhibits all
isoforms of VEGF and is Food and Drug Administration-approved only as an intravenous
therapy for metastatic colorectal cancer. There are numerous case reports and case
series on the off-label use of intravitreal bevacizumab for CNV secondary to AMD
and pathological myopia with dramatic results.45-53
Although, to the best of our knowledge, there are no specific reports on the effect
of bevacizumab on choroidal rupture-related CNV, we would expect that it may also
have a beneficial effect in these cases.
5. OCT scan of cystic macular edema secondary to BRVO before (top) and 1 week after
injection of 1.0 mg bevacizumab (bottom); Snellen visual acuity improved from 20/70 to
RETINAL VASCULAR OCCLUSIONS
Over the past 10 years, there has been substantial improvement
in the understanding of the etiology of retinal vascular occlusion, particularly
in the younger patient population. Use of birth control pills, dehydration, and
embolic events are all potential contributors to retinovascular occlusion in children
and young adults. However, no clear etiology is evident by history and review of
system in many cases. This has often resulted in an extensive workup that can include
MRI/MRA and echocardiography as well as a myriad of blood studies, including complete
blood count, folic acid, vitamin B12,
antinuclear antibody, rheumatoid factor, erythrocyte sedimentation rate, and lipid
profile. In the past, we have been disheartened by the poor yield of these tests;
however, each passing year has improved our understanding of the immune and coagulation
systems, so that now we can detect a predisposing abnormality in many patients.
Newer tests include antiphospholipid antibody profiles, antithrombin III, protein
C, protein S, prothrombin, homocysteine, C-reactive protein, factor V Leiden, and
mutations in methylene tetrahydrofolate reductase. We hope that we will learn to
better target these tests to certain clinical scenarios and perhaps even devise
in the treatment of retinal arterial occlusion has been significantly limited in
part due to delay in presentation to the ophthalmologist until after irreversible
damage has occurred. Anterior chamber paracentesis is still the only treatment that
has improved vision in our hands. However, there have been significant developments
in the treatment of retinal vein occlusion (RVO). In the late 1990s, treatment of
RVO had been largely limited to photocoagulation. The Central Vein Occlusion Study52
demonstrated no visual acuity benefit from grid laser photocoagulation for macular
edema associated with central retina vein occlusion (CRVO, Figure 4) while the Branch
Vein Occlusion Study53
demonstrated a treatment benefit with grid laser photocoagulation in some patients
with nonischemic branch retinal vein occlusion (BRVO) and less than or equal to
20/40 vision who had not improved after 3 months of observation.
Recently, there is considerable interest in new pharmacologic
treatments for RVO and secondary macular edema. Unlike macular laser treatment,
these do not require clearing of macular hemorrhages so they can be employed sooner.
Surgical and other laser therapies have also been investigated but, in our experience,
are less commonly effective. Several small retrospective as well as prospective
case series have shown at least a temporary beneficial effect with IVTA in terms
of improvement in visual acuity (VA) and reduction in central macular thickness
(CMT) on OCT for the treatment of macular edema secondary to BRVO54-60
and CRVO.61-67 Notably, VA
has not been shown to correlate with CMT. Ozdek et al61
looked at 11 nonischemic and 11 ischemic CRVO eyes and found at least a 3 line improvement
in 82% of the nonischemic group compared to only 18% of the ischemic group. Ramezani
et al62 found the therapeutic
effects of IVTA 4 mg in CRVO to be greatest in the first 2 months. In a prospective,
randomized trial involving 63 eyes with macular edema secondary to diabetic retinopathy
(DR) or RVO, Avitabile et al68
compared treatment with IVTA 4 mg, grid laser photocoagulation, or both. At each
of the 1-, 3-, and 9-month follow-up visits, VA improved 0.19 to 0.26 logMAR and
CMT decreased 29% to 37% in the IVTA alone and combination groups while the VA remained
unchanged and CMT decreased only 5% to 16% in the laser group. Hayashi et al69
performed a randomized clinical trial on 60 eyes with BRVO, comparing IVTA 4 mg
with 3 repeated retrobulbar injections of 40 mg of triamcinolone acetonide, both
groups injected 1 week after grid laser, and found IVTA to be significantly more
effective. Based on such results, the National Eye Institute is currently funding
the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study, a
multicenter, randomized, controlled clinical trial to investigate the safety and
efficacy of IVTA for the treatment of macular edema secondary to CRVO and BRVO.
The associated ocular complication rate of IVTA is relatively
high when compared with other intravitreal injections. Forty percent develop ocular
hypertension with 1% to 2% uncontrolled by medical therapy.70
Cataract extraction is performed within 1 year of treatment in 15% to 20% of injected
eyes.70 Because of its ocular
safety profile, the use of intravitreal bevacizumab for macular edema secondary
to vein occlusions has recently gained popularity (Figure 5).38,71-73
Iturralde et al71 reviewed
the results of 16 eyes injected with an average of 2.8 injections on bevacizumab
1.25 mg. Nine patients were previously given IVTA but either failed treatment or
developed ocular hypertension. The mean VA improved from a baseline of 20/600 to
20/200 at 1 month and 20/138 at 3 months, and CMT improved from 887 μm to 372
μm at 1 month.
and, to a more profound extent, bevacizumab75-79
have also been reported to cause regression of iris neovascularization (NVI), making
them much needed additions to our armamentarium for neovascular glaucoma (NVG) management,
a condition known for its dismal prognosis. Jonas et al74
treated 14 eyes with NVG (9 diabetics, 5 CRVO) with IVTA 20 mg as the only procedure
in 4 eyes, with cryotherapy in 7 eyes, with goniosynechiolysis in 1 eye, and with
phacoemulsification in 2 eyes. The degree of NVI decreased from 2.6 (±1.3)
to 1.3 (±1.2) relative units post-injection. Both intracameral and intravitreal
bevacizumab have been shown to consistently be associated with dramatic regression
of NVI within 1 week of treatment with improvement in intraocular pressure control.
These case reports suggest that the effect can last for up to 2 months post-injection.75-79
Figure 6. OCT scan of an eye with diabetic
macular edema before (top) and 2 weeks after an intravitreal injection of 4.0 mg trimacinolone
acetonide (bottom). There was transient, but marked non-infectious endophthalmitis starting
1 day after injection that cleared over the following week. Vitreous tap revealed
no organism growth. Snellen visual acuity improved from 20/70 to 20/50 despite the
The explosion in the use of intravitreal injections has generated
significant concern about another wave of iatrogenic endophthalmitis. Jager et al80
reviewed the literature from 1966 to 2004, looking at a total of 14 866 intravitreal
injections for 4382 eyes and found the overall prevalence of infectious and noninfectious
endophthalmitis to be 0.3% per injection and 0.9% per eye. The rate of infectious
endophthalmitis was 0.2% per injection and 0.5% per eye. Regarding 1739 IVTA injections,
the overall prevalence of endophthalmitis was 1.4% per injection and 0.6% per injection
for infectious endophthalmitis. IVTA injections can cause a noninfectious and self-limited
endophthalmitis (Figure 6) that may be an immune response to endotoxin or preservatives
in certain IVTA preparations; this entity usually has milder inflammation, occurs
sooner (hours to days after injection), and is painless. Intravitreal pegaptanib
has a reported infectious endophthalmitis risk of 0.16% per injection; the risk
is lower with the stricter revised injection protocol.37,81
Derived in large part from data from the VEGF Inhibition Study in Ocular Neovascularization
(VISION) trial,37,81 we have
learned that proper sterile technique, including the use of a lid speculum and 5%
povidone-iodine, can keep the endophthalmitis risk acceptably low.82
Management would usually involve vitreous tap and injection of intravitreal antibiotics
if infectious endophthalmitis is suspected.
Taban et al83
performed a review of the literature from 1963 to 2003, pooling 3 140 650 cataract
extractions and found the overall incidence of postcataract endophthalmitis to be
0.128%. Incision type was implicated in the increased incidence of postcataract
endophthalmitis in recent years, with 0.189% incidence for clear corneal incisions
vs 0.074% incidence for scleral incisions between 1992 and 2003. Using OCT, McDonnell
et al84 demonstrated that
transient postoperative IOP reduction causes the clear cornea cataract wound edge
to gape, starting at the internal aspect of the wound. Ciulla et al85
reviewed the literature from 1966 to 2000 on endopthalmitis prophalaxis for cataract
surgery and found that 5% povidone-iodine had a particularly significant inhibitory
The results of the Endophthalmitis Vitrectomy Study (EVS)86
published in 1995 showed no benefit of vitrectomy and intravitreal antibiotics over
vitreous tap and intravitreal antibiotics for postcataract endophthalmitis patients
with better than light perception vision. With modern vitrectomy technology, including
panoramic viewing, better instrumentation, and silicone oil, Kuhn and Gini87
advocated the early use of complete vitrectomy for patients with no retinal details
or a poor red reflex on ophthalmoscopy, regardless of visual acuity. They reported
a consecutive series of 47 eyes that underwent vitrectomy for infectious endopthalmitis,
91% of which recovered at least 20/40 vision compared to 53% in the EVS.
Ng et al88
in the Endopthalmitis Population Study of Western Australia (EPSWA) reviewed 213
cases of endophthalmitis between 1980 and 2000 and found that management involved
increased use of intravitreal antibiotics and decreased use of subconjuctival and
intravenous antibiotics. Other studies confirm that subconjunctival antibiotics
are probably not required in the treatment of infectious endophthalmitis.89,90
The spectrum and management of posterior segment emergencies continues
to evolve. Recent advances have resulted in better diagnosis and management of several
posterior segment emergencies, including posterior segment trauma, retinal vascular
occlusions, and endophthalmitis. Improved imaging modalities, vitrectomy technology,
and anesthesia approaches have permitted more expeditious care of the traumatized
Pharmaceutical developments have added to the outpatient armamentarium;
in particular, anti-VEGF therapies have revolutionalized not only how we manage
exudative AMD, but also other causes of CNV, retinal vein occlusions, and neovascular
glaucoma. Endophthalmitis continues to be a concern in the era of clear corneal
cataract surgery and frequent use of intravitreal injections.
1. Negrel AD, Thylefors B. The global impact of eye injuries.
Ophthalmic Epidemiol. 1998;5:143-169.
2. Schrader WF. Open globe injuries: epidemiological study of
two eye clinics in germany, 1981-1999. Croat Med J. 2004;45:268-274.
3. Conn JM, Annest JL, Gilchrist J, Ryan GW. Injuries from paintball
game related activities in the united states, 1997-2001. Inj Prev. 2004;10:139-143.
4. Fineman MS. Ocular paintball injuries. Curr Opin Ophthalmol.
5. Listman DA. Paintball injuries in children: more than meets
the eye. Pediatrics. 2004;113:e15-18.
6. Pearlman JA, Au Eong KG, Kuhn F, Pieramici DJ. Airbags and
eye injuries: epidemiology, spectrum of injury, and analysis of risk factors. Surv
7. McGwin G Jr, Owsley C. Risk factors for motor vehicle collision-related
eye injuries. Arch Ophthalmol. 2005;123:89-95.
8. Duma SM, Rath AL, Jernigan MV, Stitzel JD, Herring IP. The
effects of depowered airbags on eye injuries in frontal automobile crashes. Am
J Emerg Med. 2005;23:13-
9. Lehto KS, Sulander PO, Tervo TM. Do motor vehicle airbags
increase risk of ocular injuries in adults? Ophthalmology. 2003;110:1082-1088.
10. Zinreich SJ, Miller NR, Aguayo JB, Quinn C, Hadfield R, Rosenbaum
AE. Computed tomographic three-dimensional localization and compositional evaluation
of intraocular and orbital foreign bodies. Arch Ophthalmol. 1986;104:1477-1482.
11. Lindahl S. Computed tomography of intraorbital foreign bodies.
Acta Radiol. 1987;28:235-240.
12. Etherington RJ, Hourihan MD. Localisation of intraocular and
intraorbital foreign bodies using computed tomography. Clin Radiol. 1989;40:610-614.
13. Chacko JG, Figueroa RE, Johnson MH, Marcus DM, Brooks SE.
Detection and localization of steel intraocular foreign bodies using computed tomography.
A comparison of helical and conventional axial scanning. Ophthalmology. 1997;104:319-323.
14. Lakits A, Prokesch R, Scholda C, Bankier A. Orbital helical
computed tomography in the diagnosis and management of eye trauma. Ophthalmology.
15. Dass AB, Ferrone PJ, Chu YR, Esposito M, Gray L. Sensitivity
of spiral computed tomography scanning for detecting intraocular foreign bodies.
16. Fisher YL. Advances in contact ophthalmic ultrasonography:
Ocular trauma and intraocular foreign body patients. Dev Ophthalmol. 1989;18:69-74.
17. Rubsamen PE, Cousins SW, Winward KE, Byrne SF. Diagnostic
ultrasound and pars plana vitrectomy in penetrating ocular trauma. Ophthalmology.
18. Bryden FM, Pyott AA, Bailey M, McGhee CN. Real time ultrasound
in the assessment of intraocular foreign bodies. Eye. 1990;4 (Pt 5):727-731.
19. Barash D, Goldenberg-Cohen N, Tzadok D, Lifshitz T, Yassur
Y, Weinberger D. Ultrasound biomicroscopic detection of anterior ocular segment
foreign body after trauma. Am J Ophthalmol. 1998;126:197-202.
20. Deramo VA, Shah GK, Baumal CR, et al. The role of ultrasound
biomicroscopy in ocular trauma. Trans Am Ophthalmol Soc. 1998;96:355-365;
21. Lagouros PA, Langer BG, Peyman GA, Mafee MF, Spigos DG, Grisolano
J. Magnetic resonance imaging and intraocular foreign bodies. Arch Ophthalmol.
22. LoBue TD, Deutsch TA, Lobick J, Turner DA. Detection and localization
of nonmetallic intraocular foreign bodies by magnetic resonance imaging. Arch
23. Williams S, Char DH, Dillon WP, Lincoff N, Moseley M. Ferrous
intraocular foreign bodies and magnetic resonance imaging. Am J Ophthalmol.
24. Williamson TH, Smith FW, Forrester JV. Magnetic resonance
imaging of intraocular foreign bodies. Br J Ophthalmol. 1989;73:555-558.
25. Glatt HJ, Custer PL, Barrett L, Sartor K. Magnetic resonance
imaging and computed tomography in a model of wooden foreign bodies in the orbit.
Ophthal Plast Reconstr Surg. 1990;6:108-114.
26. Ambler JS, Meyers SM. Management of intraretinal metallic
foreign bodies without retinopexy in the absence of retinal detachment. Ophthalmology.
27. Kelsey CA, King JN, Keck GM, Chiu MT, Wolfe DM, Orrison WW.
Ocular hazard of metallic fragments during mr imaging at 0.06 t. Radiology.
28. MacCumber MW and Zanger MW. Open-Globe Injuries. Focal Points:
Clinical Modules for Ophthalmologists, Module 7, 2001.
29. Pieramici DJ et al. The prognostic significance of a system
for classifying mechanical injuries of the eye (globe) in open-globe injuries. J
30. Scott IU, Gayer S, Voo I, Flynn HW, Jr., Diniz JR, Venkatraman
A. Regional anesthesia with monitored anesthesia care for surgical repair of selected
open globe injuries. Ophthalmic Surg Lasers Imaging. 2005;36:122-128.
31. Scott IU, McCabe CM, Flynn HW, et al. Local anesthesia with
intravenous sedation for surgical repair of selected open globe injuries. Am
J Ophthalmol. 2002;134:707-711.
32. Boscia F, La Tegola MG, Columbo G, Alessio G, Sborgia C. Combined
topical anesthesia and sedation for open-globe injuries in selected patients. Ophthalmology.
33. Fedrat S and de Juan E. Timing Guidelines for Emergent
Surgery in Management of Ocular Injuries and Emergencies. Philadelphia: Lippincott,
Williams & Wilkins, 1998. pp 79-89.
34. Arroyo JG et al. A matched study of primary scleral buckle
placement during repair of posterior segment open globe injujries. Br J Ophthalmol.
35. Photodynamic therapy of subfoveal choroidal neovascularization
in age-related macular degeneration with verteporfin: one-year results of 2 randomized
clinical trialstap report. Treatment of age-related macular degeneration with
photodynamic therapy (tap) study group. Arch Ophthalmol. 1999;117:1329-1345.
36. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy
with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.
37. Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer
DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med.
38. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography
findings after an intravitreal injection of bevacizumab (avastin) for macular edema
from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336-339.
39. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment
of neovascular age-related macular degeneration: a phase i/ii multicenter, controlled,
multidose study. Ophthalmology. 2006;113:642 e641-644.
40. Benson WE SJ, Sarin LK. Blunt trauma. Philadelphia:
41. Kelley J. Traumatic chorioretinopathies. Philadelphia:
Elsevier Mosby; 2006.
42. Conrath J, Forzano O, Ridings B. Photodynamic therapy for
subfoveal cnv complicating traumatic choroidal rupture. Eye. 2004;18:946-947
43. Harissi-Dagher M, Sebag M, Gauthier D, Marcil G, Labelle P,
Arbour JD. Photodynamic therapy in young patients with choroidal neovascularization
following traumatic choroidal rupture. Am J Ophthalmol. 2005;139:726-728.
44. Mennel S, Hausmann N, Meyer CH, Peter S. Photodynamic therapy
and indocyanine green guided feeder vessel photocoagulation of choroidal neovascularization
secondary to choroid rupture after blunt trauma. Graefes Arch Clin Exp Ophthalmol.
45. Yamamoto I, Rogers AH, Reichel E, Yates P, Duker JS. Intravitreal
bevacizumab (avastin) as treatment for subfoveal choroidal neovascularization secondary
to pathologic myopia. Br J Ophthalmol. 2006 Jul 26; [Epub ahead of print].
46. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi
CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization
in age-related macular degeneration. Am J Ophthalmol. 2006;142:1-9.
47. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety
and efficacy of intravitreal bevacizumab (avastin) for neovascular age-related macular
degeneration. Retina. 2006;26:495-511.
48. Ladewig MS, Ziemssen F, Jaissle G, et al. [intravitreal bevacizumab
for neovascular age-related macular degeneration]. Ophthalmologe. 2006;103:463-470.
49. Ladewig MS, Ziemssen F, Jaissle G, et al. [intravitreal bevacizumab
for neovascular age-related macular degeneration.] Ophthalmologe. 2006 May;
[Epub ahead of print].
50. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA,
Giust MJ. Intravitreal bevacizumab (avastin) for neovascular age-related macular
degeneration. Ophthalmology. 2006;113:363-372 e365.
51. Reichel E. Intravitreal bevacizumab for choroidal neovascularization
and cystoid macular edema: a cost-effective treatment? Ophthalmic Surg Lasers
52. Evaluation of grid pattern photocoagulation for macular edema
in central vein occlusion. The central vein occlusion study group m report. Ophthalmology.
53. Argon laser photocoagulation for macular edema in branch vein
occlusion. The branch vein occlusion study group. Am J Ophthalmol. 1984;98:271-282.
54. Cheng KC, Wu WC. Intravitreal triamcinolone acetonide for
patients with macular edema due to branch retinal vein occlusion. Kaohsiung J
Med Sci. 2006;22:321-330.
55. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone
for the treatment of ischemic macular edema associated with branch retinal vein
occlusion. Am J Ophthalmol. 2006;141:876-883.
56. Chen SD, Lochhead J, Patel CK, Frith P. Intravitreal triamcinolone
acetonide for ischaemic macular oedema caused by branch retinal vein occlusion.
Br J Ophthalmol. 2004;88:154-155.
57. Prasad AG, Shah GK. Intravitreal triamcinolone for ischemic
branch retinal vein occlusion with serous retinal detachment. Retina. 2006;26:234-236.
58. Karacorlu M, Ozdemir H, Karacorlu SA. Resolution of serous
macular detachment after intravitreal triamcinolone acetonide treatment of patients
with branch retinal vein occlusion. Retina. 2005;25:856-860.
59. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone
injection for treatment of macular edema secondary to branch retinal vein occlusion.
60. Krepler K, Ergun E, Sacu S, Richter-Muksch S, Wagner J, Stur
M, Wedrich A. Intravitreal triamcinolone acetonide in patients with macular oedema
due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand. 2005;83:600-604.
61. Ozdek SC, Aydin B, Gurelik G, Bahceci U, Hasanreisoglu B.
Effects of intravitreal triamcinolone injection on macular edema and visual prognosis
in central retinal vein occlusion. Int Ophthalmol. 2006 Jun 16; [Epub ahead
62. Ramezani A, Entezari M, Moradian S, Tabatabaei H, Kadkhodaei
S. Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized
clinical trial. Graefes Arch Clin Exp Ophthalmol. 2006 Jun 1; [Epub ahead
63. Gelston CD, Olson JL, Mandava N. Macular oedema in central
retinal vein occlusion treated with intravitreal triamcinolone. Acta Ophthalmol
64. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF.
Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion.
Eur J Ophthalmol. 2005;15:751-758.
65. Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone
acetonide for the treatment of central retinal vein occlusion in young patients.
66. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone
treatment for macular edema associated with central retinal vein occlusion and hemiretinal
vein occlusion. Retina. 2005;25:846-850.
67. Tewari HK, Sony P, Chawla R, Garg SP, Venkatesh P. Prospective
evaluation of intravitreal triamcinolone acetonide injection in macular edema associated
with retinal vascular disorders. Eur J Ophthalmol. 2005;15:619-626.
68. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone
compared with macular laser grid photocoagulation for the treatment of cystoid macular
edema. Am J Ophthalmol. 2005;140:695-702.
69. Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections
of triamcinolone for macular edema associated with branch retinal vein occlusion.
Am J Ophthalmol. 2005;139:972-982.
70. Jonas JB. Intravitreal triamcinolone acetonide for treatment
of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand.
71. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab
(avastin) treatment of macular edema in central retinal vein occlusion: a short-term
study. Retina. 2006;26:279-284.
72. Spandau UH, Ihloff AK, Jonas JB. Intravitreal bevacizumab
treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol
73. Jaissle GB, Ziemssen F, Petermeier K, et al. [bevacizumab
for treatment of macular edema secondary to retinal vein occlusion]. Ophthalmologe.
74. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Regression of
neovascular iris vessels by intravitreal injection of crystalline cortisone. J
75. Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L, Scott
IU. Short-term results of intravitreal bevacizumab (avastin) on anterior segment
neovascularization in neovascular glaucoma. Acta Ophthalmol Scand. 2006;84:556-557.
76. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab
in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37:144-146.
77. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis
iridis from a single bevacizumab (avastin) injection. Retina. 2006;26:354-356.
78. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt
KU. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142:158-160.
79. Avery RL. Regression of retinal and iris neovascularization
after intravitreal bevacizumab (avastin) treatment. Retina. 2006;26:352-354.
80. Jager RD, Aiello LP, Patel SC, Cunningham ET, Jr. Risks of
intravitreous injection: A comprehensive review. Retina. 2004;24:676-698.
81. D'Amico DJ, Patel M, Adamis AP, Cunningham ET, Jr., Guyer
DR, Katz B. Pegaptanib sodium for neovascular age-related macular degeneration:
two-year safety results of the two prospective, multicenter, controlled clinical
trials. Ophthalmology. 2006;113:1001 e1001-1006.
82. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines
for intravenous injections. Retina. 2004;24:S3-S19.
83. Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis
following cataract surgery: A systematic review of the literature. Arch Ophthalmol.
84. McDonnell PJ, Taban M, Sarayba M, et al. Dynamic morphology
of clear corneal cataract incisions. Ophthalmology. 2003;110:2342-2348.
85. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis
for cataract surgery: an evidence-based update. Ophthalmology. 2002;109:13-24.
86. Results of the endophthalmitis vitrectomy study. A randomized
trial of immediate vitrectomy and of intravenous antibiotics for the treatment of
postoperative bacterial endophthalmitis. Endophthalmitis vitrectomy study group.
Arch Ophthalmol. 1995;113:1479-1496.
87. Kuhn F, Gini G. Vitrectomy for endophthalmitis. Ophthalmology.
88. Ng JQ, Morlet N, Pearman JW, et al. Management and outcomes
of postoperative endophthalmitis since the endophthalmitis vitrectomy study: the
endophthalmitis population study of western australia (epswa)'s fifth report. Ophthalmology.
89. Smiddy WE, Smiddy RJ, Ba'Arath B, et al. Subconjunctival antibiotics
in the treatment of endophthalmitis managed without vitrectomy. Retina. 2005;25:751-758.
90. Iyer MN, Han DP, Yun HJ, et al. Subconjunctival antibiotics
for acute postcataract extraction endophthalmitisis it necessary? Am J
Ho, MD is a second year vitreoretinal fellow with Illinois Retina Associates/ Rush
University Medical Center (Chicago) and trained as a resident in the Wills Eye Hospital
Emergency Department in Philadelphia. Mathew W. MacCumber, MD, PhD is associate
professor, associate chairman for research, and vitreoretinal fellowship director
in the Department of Ophthalmology, Rush University Medical Center, and a partner
with Illinois Retina Associates in Chicago. Dr. MacCumber has consulted for and/or
received grant support from Genentech, Novartis, Eyetech/OSI, Allergan, Bausch &
Lomb, and Optos, Inc. The authors have no financial interest in information
presented in this article.
Retinal Physician, Issue: September 2006